AR082004A1 - Compuestos de fusion de piridina - Google Patents
Compuestos de fusion de piridinaInfo
- Publication number
- AR082004A1 AR082004A1 ARP110102108A ARP110102108A AR082004A1 AR 082004 A1 AR082004 A1 AR 082004A1 AR P110102108 A ARP110102108 A AR P110102108A AR P110102108 A ARP110102108 A AR P110102108A AR 082004 A1 AR082004 A1 AR 082004A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heterocycloalkyl
- haloalkoxy
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000004927 fusion Effects 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 5
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 5
- 125000001188 haloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- -1 cyano, hydroxy Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se refiere a moduladores duales de los receptores de la 5-HT2A y de la D3. La presente se refiere además a la obtención de los compuestos de la fórmula (1), a composiciones farmacéuticas que los contienen y a su utilización como medicamentos.Reivindicación 1: Un compuesto de la fórmula (1) en la que: X es O ó S; Y es -C(O)- o -S(O)2-; A es un enlace sencillo o un doble enlace, con la condición de que si X es S, entonces A sea un doble enlace; R1 es hidrógeno, alquilo C1-7, haloalquilo C1-7, alquenilo C2-7, alquinilo C2-7, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -N(R6)2, dichos alquilo C1-7, haloalquilo C1-7, alquenilo C2-7, alquinilo C2-7 están opcionalmente sustituidos de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por ciano, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo y -S(O)2R7 y dichos cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R4 independientes; R2, R3 son con independencia hidrógeno, halógeno, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7 o haloalcoxi C1-7; R4 es halógeno, ciano, alquilo C1-7, haloalquilo C1-7, cicloalquilo, heterocicloalquilo, arilo, arilo fusionado con un heterocicloalquilo, heteroarilo, -C(O)N(R6)2, -N(R6)2, -NH(CO)-alquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7, oxo, -S(O)2R7 o alquilo C1-7 sustituido de una a tres veces por sustituyentes elegidos con independencia entre el grupo formado por ciano, hidroxi, alcoxi C1-7 y haloalcoxi C1-7, dichos cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos de una a tres veces por R5 independientes; R5 es halógeno, ciano, alquilo C1-7, haloalquilo C1-7, hidroxi, alcoxi C1-7, haloalcoxi C1-7 u oxo; R6 es hidrógeno o alquilo C1-7; R7 es hidrógeno, alquilo C1-7 o arilo, dicho arilo está opcionalmente sustituido de una a tres veces por R5 independientes; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10166652 | 2010-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082004A1 true AR082004A1 (es) | 2012-11-07 |
Family
ID=44260006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102108A AR082004A1 (es) | 2010-06-21 | 2011-06-17 | Compuestos de fusion de piridina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8586579B2 (es) |
| EP (1) | EP2582705B1 (es) |
| JP (1) | JP2013529610A (es) |
| KR (1) | KR20130120997A (es) |
| CN (1) | CN102947310B (es) |
| AR (1) | AR082004A1 (es) |
| BR (1) | BR112012032748A2 (es) |
| CA (1) | CA2792966A1 (es) |
| ES (1) | ES2508170T3 (es) |
| MX (1) | MX2012013637A (es) |
| RU (1) | RU2012157404A (es) |
| TW (1) | TW201204737A (es) |
| WO (1) | WO2011161009A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000032987A (ja) * | 1998-07-16 | 2000-02-02 | Dai Ichi Seiyaku Co Ltd | Ｄｎａ |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8722683B2 (en) * | 2011-02-17 | 2014-05-13 | Hoffmann La-Roche Inc. | Benzodioxole piperazine compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (es) * | 2013-03-15 | 2014-10-31 | Abbvie Inc | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| AR095264A1 (es) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3 |
| CN104140421B (zh) * | 2013-05-08 | 2017-04-05 | 上海医药工业研究院 | 苯并异噻唑类化合物及在制备抗精神分裂症药物中的应用 |
| EP3495363B1 (en) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect |
| US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
| TW201938537A (zh) | 2018-01-26 | 2019-10-01 | 日商鹽野義製藥股份有限公司 | 具有多巴胺ｄ３受體拮抗作用的稠環化合物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| BRPI0707960A2 (pt) | 2006-02-17 | 2011-05-10 | Hoffmann La Roche | derivados de benzoil-piperidina como moduladores de 5ht2/d3, medicamento e uso dos mesmos |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| CN101778820B (zh) | 2007-08-09 | 2012-12-05 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht2a和d3受体双重调节剂的苯甲酰基-哌啶衍生物 |
| CN102159557A (zh) | 2008-09-22 | 2011-08-17 | 弗·哈夫曼-拉罗切有限公司 | 哌嗪d3和5-ht2a受体调节剂 |
| WO2010034656A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors |
| BRPI0918985A2 (pt) | 2008-09-23 | 2015-12-01 | Hoffmann La Roche | derivados de benzo[d]isoxazol-3-il-piperazina úteis como moduladores dos receptores d3 de dopamina |
| US8470828B2 (en) * | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
-
2011
- 2011-06-16 US US13/161,548 patent/US8586579B2/en not_active Expired - Fee Related
- 2011-06-17 ES ES11727156.9T patent/ES2508170T3/es active Active
- 2011-06-17 KR KR1020127033220A patent/KR20130120997A/ko not_active Application Discontinuation
- 2011-06-17 MX MX2012013637A patent/MX2012013637A/es active IP Right Grant
- 2011-06-17 EP EP11727156.9A patent/EP2582705B1/en not_active Not-in-force
- 2011-06-17 BR BR112012032748A patent/BR112012032748A2/pt not_active IP Right Cessation
- 2011-06-17 CA CA2792966A patent/CA2792966A1/en not_active Abandoned
- 2011-06-17 JP JP2013515819A patent/JP2013529610A/ja active Pending
- 2011-06-17 RU RU2012157404/04A patent/RU2012157404A/ru not_active Application Discontinuation
- 2011-06-17 WO PCT/EP2011/060080 patent/WO2011161009A1/en active Application Filing
- 2011-06-17 TW TW100121273A patent/TW201204737A/zh unknown
- 2011-06-17 CN CN201180030998.4A patent/CN102947310B/zh not_active Expired - Fee Related
- 2011-06-17 AR ARP110102108A patent/AR082004A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102947310A (zh) | 2013-02-27 |
| EP2582705A1 (en) | 2013-04-24 |
| MX2012013637A (es) | 2013-01-24 |
| CA2792966A1 (en) | 2011-12-29 |
| JP2013529610A (ja) | 2013-07-22 |
| CN102947310B (zh) | 2015-11-25 |
| EP2582705B1 (en) | 2014-08-06 |
| BR112012032748A2 (pt) | 2016-11-08 |
| RU2012157404A (ru) | 2014-07-27 |
| US20110313151A1 (en) | 2011-12-22 |
| TW201204737A (en) | 2012-02-01 |
| ES2508170T3 (es) | 2014-10-16 |
| KR20130120997A (ko) | 2013-11-05 |
| WO2011161009A1 (en) | 2011-12-29 |
| US8586579B2 (en) | 2013-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados | |
| AR093184A1 (es) | Compuesto de pirimidina sustituida como inhibidor de quinurenina-3-monooxigenasa y composicion farmaceutica que lo comprenden | |
| PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
| AR073136A1 (es) | Compuestos de pirrol | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| ES2626801T3 (es) | Compuestos de triazolopiridina como inhibidores de pde10a | |
| AR051995A1 (es) | Derivados de tieno-piridina como intensificadores alostericos de gaba -b | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| NI201000049A (es) | Método para producir 2'-desoxi-5-azacitidina (decitabina) | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| CO6251363A2 (es) | Derivados de indol-2-ona disustituidos en 3 su preparacion y su aplicacion en terapeutica | |
| AR085236A1 (es) | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d | |
| AR067873A1 (es) | Derivados de benzoil-piperidina como moduladores duales de receptores de 5-ht2a y de d3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |